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ABSTRACT 
The increased prevalence of chronic kidney disease (CKD) has become a major 
global health burden. This increase in CKD burden parallels the increase in hypertension 
prevalence. In addition, increasing evidence suggest that genetics play a strong role in the 
susceptibility for renal disease. Inbred mouse strains C57BL/6 and 129S6/SvEv differ in 
their susceptibility to kidney disease when subjected to hypertension using the DOCA/salt 
uninephrectomy model of hypertension. Similar to others, we found the 129S6/SvEv mice 
to be susceptible to develop severe glomerulosclerosis, whereas the C57BL/6 mice are 
comparatively resistant. To identify new candidate genes that are involved in the 
pathogenesis of glomerular disease, we used microarray technology to compare the 
glomerular transcriptome of both strains and determine changes in glomerular gene 
expression when subjected to the DOCA/salt uninephrectomy model of systemic 
hypertension. This approach was accompanied with ultrastructural analysis and glomerular 
stiffness measurements to identify corresponding structural changes. Here, we have 
identified novel genes associated with strain differences and hypertension, and we used 
immunohistochemistry to validate their expression in podocytes and glomerular arterioles 
in murine and human kidneys. The increased understanding of the molecular mechanisms 
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underlying hypertension-associated podocyte injury and glomerular damage which will 
result from these studies, will ultimately lead to identification of novel pharmacologic 
targets or therapeutic strategies for patients with hypertension and renal disease. 
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Chapter 1: Introduction 
Chronic Kidney Disease 
 Chronic kidney disease (CKD) is a worldwide public health problem with a rising 
incidence and prevalence. It is recognized as a common condition that is associated with 
an increased risk of cardiovascular disease and ultimately lead to end-stage renal failure, 
and premature death. The Kidney Disease Outcomes Quality Initiative (K/DOQI) of the 
National Kidney Foundation (NKF) defines chronic kidney disease as either kidney 
damage or a decreased glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2 
for 3 or more months. Kidney disease severity is classified into five stages according to the 
level of GFR (Table 1).  
 
Table 1. Stages of CKD based on measured or estimated GFR. 
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Epidemiology 
The number of incident end-stage renal disease (ESRD) cases has increased 
between 1980s and 1990s at a rapid rate 1. Although the exact reasons for this rapid growth 
are unknown, it is been postulated that under-recognition of risk factors for chronic kidney 
disease (CKD) and early stages of CKD, changes in patient demographics, and variations 
of disease outcome among racial groups, may in part explain this significant growth 2. 
However, according to the 2009 annual report by the USRDS, the incidence of ESRD in 
the United States has reached a plateau since 20011,3. Aggressive control of blood pressure 
with drugs that block the renin-angiotensin system and tighter glycemic control among 
patients with diabetes can be attributed to this hopeful change in incident rate4. 
The incidence of ESRD varies considerably across patient subgroups. In the United 
States, the incidence of ESRD among African-Americans is strikingly higher than the 
incidence among European Americans 5. African Americans constitute more than 32% of 
all patients in the U.S. receiving dialysis for kidney failure, but only represent 13% of the 
overall U.S. population 5. This disproportionate risk may be partially explained by 
differences in social-economic status, lifestyle factors and clinical factors such as blood 
pressure control, but most of the increased risk remains unexplained. Genome-wide 
association studies have linked non-muscle myosin heavy chain 9 gene (MYH9) single-
nucleotide polymorphisms (SNPs) with increased nephropathy susceptibility in African 
Americans 6. The gene encoding apolipoprotein L1 (APOL1) is in close proximity to 
MYH9 on chromosome 22, and variations in APOL1 have recently been shown to be more 
intensely associated with CKD risk 7,8. Incidence rates are also elevated among those of 
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Hispanic and Asian ethnicity, but the increased risk is less than that for African Americans. 
Moreover, the incidence of ESRD has been increasing most rapidly among adults over 70 
years of age1. However, the cause of CKD often is not readily apparent in many elderly 
patients. Epidemiological evidence suggests that vascular disease may be the predominant 
etiology for CKD in this population9.  
Sex has been long recognized as an important factor in the development of CKD. 
Kidney disease progression is more significant among males10. Sex-based genetic 
variability has been linked to differences in blood pressure. Genetic-based differences in 
blood pressure and sex hormone influences may partially explain the disproportionate 
effects. Some subtle differences in renal mass and structure have been reported in men 
compared with women, and these may also contribute to sex-associated differences in 
susceptibility. 
Chronic Kidney Disease Risk Factors 
In general, risk factors for development of CKD would include susceptibility 
factors, initiation factors, and progression factors. Susceptibility factors are characteristics 
that put an individual at risk for kidney damage following exposure to an initiation factor. 
These factors can be developmental, such as low birth weight resulting in low nephron 
numbers, or genetic, such as gene polymorphisms. Elderly populations, US ethnic 
minorities, and individuals with low income or education are also at increased risk of 
kidney damage11,12. Initiation factors are conditions that directly initiate kidney injury in 
an individual who is susceptible to kidney injury. Diabetes, hypertension, autoimmune 
disorders, infections, kidney stones, cystic kidneys and medications are common initiation 
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factors of kidney injury11,12. Individuals with susceptibility and/or initiation factors are at 
higher risk of developing kidney damage and therefore should be tested for markers of 
kidney injury more frequently and on a regular basis. Early detection and initiation of 
intervention can slow disease progression. Moreover, other factors can influence the rate 
of decline in kidney function irrespective of the original cause of kidney damage in patients 
with CKD. These factors are known as progression factors, and include uncontrolled 
hypertension, poor glycemic control in diabetes, overt proteinuria, anemia, and smoking13. 
These factors are considered modifiable, and when treated or managed, can stabilize kidney 
function for years 13.  
Pathophysiology 
Overview 
When nephrons are damaged or lost through disease, the remaining or least affected 
nephrons undergo significant changes to compensate for the loss in renal function. 
However, the kidney's ability to maintain the composition of the extracellular fluid is well 
preserved until late in the course of CKD, as a result of compensatory responses in the 
remaining viable nephrons. These compensatory physiological responses result in 
hypertrophy of the nephrons and increased glomerular filtration14. However, when enough 
damage has occurred such that GFR falls below a critical level, a downward progressive 
spiral to ESRD ensues, even when the initial disease causing CKD is treated and controlled. 
The rate of decline of GFR follows a near constant linear relationship with time, allowing 
an accurate prediction when ESRD would be reached and when replacement therapy is 
required. Intriguingly, the GFR to time relationship was found to be characteristic of 
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individual patients rather than renal disease specific15. This observation suggested that the 
progressive nature of renal disease could be attributed to a final common pathway of 
mechanisms, independent of the primary cause of nephropathy15. This common pathway 
theory states that CKD occurs through local nephron loss and that the adaptive responses 
of surviving nephrons ultimately prove detrimental to the kidney16. Over time, 
glomerulosclerosis and tubular atrophy further reduce nephron number, fueling a self-
perpetuating cycle of nephron destruction, culminating in uremia.  
Given the growing worldwide burden of CKD that causes substantial morbidity and 
mortality in individuals and threatens to overburden health care systems, it could be argued 
that the further elucidation of the mechanisms of CKD progression resulting in more 
effective interventions to slow its advance should remain among the highest priorities for 
nephrologists today.  
Structural and Functional Adaptations of the Glomerulus 
Compensatory kidney enlargement in response to loss of a whole kidney has been 
a well-recognized phenomenon since antiquity. This phenomenon has been studied in a 
variety of species, but predominantly in rodents following uninephrectomy. In animal 
models, increased glomerular tuft volume is the major morphometric change following 
uninephrectomy, detected as early as 4 days, and appears to parallel whole kidney growth17. 
Both the superficial and juxtamedullary glomeruli enlarge in response to uninephrectomy. 
There is agreement that glomerular capillaries increase in length and number with more 
branches, but most studies show that diameter or cross sectional surface area of the 
glomerular capillaries remains constant or increases only minimally18. Intriguingly, 
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transplantation of hypertrophied kidneys into uninephrectomized recipients demonstrated 
regression of glomerular hypertrophy; however, the increase in capillary length was 
maintained19. Glomerular volume in these models was evaluated by increased protein to 
DNA ratio and by electron microscopy. The initial increase in glomerular tuft volume was 
mainly due to podocyte hypertrophy and secondarily to mesangial matrix expansion20,21.  
Early studies highlighted the importance of glomerular hypertrophy and the concept 
of mechanical aggression. In the early 1980’s, several clinical and experimental studies 
showed that enlargement of the glomerular tuft was consistently associated with the 
development of progressive glomerular injury22. Glomerular hemodynamic responses to 
nephron loss have been widely studied in animals subjected to surgical ablation of kidney 
mass. Nephron loss in rodents resulted in a remarkable increase in GFR few days after 
surgery. For instance, after uninephrectomy, the GFR of the remaining kidney increased 
maximally by 50% within 8 days; after 5/6 nephrectomy, the increase in the GFR of the 
remnant kidney was maximal at 300% within 16 days23. Some studies implied that the 
development of glomerular injury was more closely associated to glomerular hypertrophy 
than with glomerular hypertension. In these studies glomerular hypertrophy predicted the 
development of glomerulosclerosis in proteinuric patients22, while experimental 
observation indicated development of glomerulosclerosis without evidence of glomerular 
hypertension24.  
The identification of a rat strain, Munich-Wistar, facilitated the study of glomerular 
hemodynamics because of the unusual finding in this strain of glomeruli near the kidney 
surface. Micropuncture studies in these rats allowed the direct measurement of the 
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intraglomerular pressure in models of renal mass ablation, and lead to understanding of the 
mechanisms underlying the compensatory increase in GFR. The increase in GFR following 
uninephrectomy was attributed to an increase in a single nephron GFR, which was mainly 
achieved by an increase in glomerular plasma flow rate, which resulted from dilatation of 
the afferent and efferent arterioles. The dilation in the afferent arteriole, however, was 
proportionately greater than in the efferent arteriole. Moreover, with more extensive 
nephron loss, even greater compensatory increases in single nephron GFR were observed. 
Although systemic blood pressure was not elevated, hydraulic pressure in the glomerular 
capillaries and the transcapillary hydraulic pressure gradient were increased significantly 
post-uninephrectomy25. Further studies indicated that glomerular hemodynamic responses 
to nephron loss seem to be similar between the superficial cortical and juxtamedullary 
nephrons26. 
The rise in single nephron GFR associated with renal mass ablation is often referred 
to as glomerular hyperfiltration, and the elevated transcapillary hydraulic pressure is 
termed glomerular hypertension. Together these terms encompass the central concepts 
underlying the hemodynamic adaptations in the remnant kidney. In humans, the effects of 
nephron loss on the physiology of the remnant kidney have been studied mainly in healthy 
individuals undergoing donor nephrectomy for kidney transplantation. Inulin-clearance 
studies of the earliest kidney donors revealed that total GFR in the donor’s remaining 
kidney increased to 65% to 70% of the previous two-kidney value by 1 week post-
nephrectomy27. However, there is currently no method for estimating single nephron GFR 
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or glomerular capillary pressure in vivo, and more detailed assessments of glomerular 
hemodynamics in humans have thus not yet been possible. 
Mediators of Glomerular Hemodynamic Responses: 
The effector mechanisms responsible for the hemodynamic changes in response to 
reduced renal mass have been widely studied. Several factors including angiotensin II, 
aldosterone, cytokines, growth factors, endothelins, and natriuretic peptides have been 
implicated in glomerular hemodynamic adaptative responses28. The actions of angiotensin 
II are primarily related to its effects on vascular tone and fluid balance that are mediated 
through angiotensin II type-1 receptors (AT1) in the heart, brain, kidneys, adrenals, and the 
vasculature. In vascular smooth muscle, stimulation of AT1 receptors by angiotensin II 
induces cell contraction and consequent vasoconstriction. In the adrenal cortex, this ligand-
receptor interaction stimulates aldosterone release, thereby promoting sodium resorption 
in the distal nephron14. Moreover, angiotensin II directly enhances sodium retention by the 
proximal tubule, and in the brain, it stimulates thirst and salt craving. Additional effects 
include sympatho-adrenal stimulation and the augmentation of cardiac contractility. 
Together these effects serve to maintain extracellular fluid volume and the systemic blood 
pressure. The effects of exogenous administration of angiotensin II on the kidney are dose 
dependent. Infusion of low doses has no effect on the GFR but does increase renal vascular 
resistance and reduced renal blood flow. On the other hand, higher doses of angiotensin II 
further increased renal vascular resistance resulting in even further reduction in renal blood 
flow and as a sequence, decrease in GFR29. Severe volume depletion results in robust 
activation of the renin angiotensin system that would result in angiotensin II-dependent 
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reduced renal blood flow and stimulation of tubular sodium reabsorption in order to 
maintain the systemic blood pressure. Micropuncture studies have been used to identify 
intrarenal sites of angiotensin II effects. These studies demonstrated that acute infusion 
with angiotensin II increases both afferent and efferent arteriolar resistance and also 
increased the intraglomerular capillary pressure30. However, chronic angiotensin II 
infusion with sustained intraglomerular hypertension leads to glomerular capillary damage 
and proteinuria besides systemic hypertension. Similar results were observed in both 
normal and uninephrectomized rats31. 
The role of endogenous angiotensin II in glomerular hemodynamics have been 
delineated by the use of pharmacological inhibitors of the renin angiotensin system in 
remnant kidney models. Chronic treatment of 5/6 nephrectomized rats with either an 
angiotensin converting enzyme inhibitor (ACEI) or angiotensin II (subtype 1) receptor 
antagonist results in normalization of glomerular capillary pressure through reduction in 
systemic blood pressure and dilatation of both afferent and efferent arterioles28,32.  
Hypertension and Chronic Kidney Disease 
Hypertension represents today a major public concern. In fact, it affects nearly half 
of the adult population worldwide according to the World Health Statistics 2012 33. In the 
US, it affects almost one-third (66.9 million) of the adult population, of whom more than 
half (35.8 million) have uncontrolled hypertension34. About 90% of hypertension is 
classified as primary hypertension (also called essential hypertension) after exclusion of 
known and curable causes. Hypertension is a major risk factor for cardiovascular mortality 
and morbidity through its effects on target organs like the brain, heart, and kidney. The 
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presence of high blood pressure levels significantly increases the risk of kidney disease. In 
fact, hypertension is the second leading cause of CKD and ESRD in the U.S. after diabetes1.  
Patients with pre-existing renal disease and/or diabetes exhibit a greatly enhanced 
susceptibility to accelerated renal damage even with mild-to-moderate hypertension35. 
Moreover, subtle target organ damage, including kidney damage indicated by 
microalbuminuria, takes place early in the course of hypertension and can be left 
unrecognized until major complications occur. The kidneys are one of the key organs 
affected by mechanical forces in hypertension patients and the relationship between 
hypertension and chronic kidney disease (CKD) remains perplexing especially with 
evidence supporting that hypertension is both a “cause and effect” of CKD14. 
Renal damage is a frequent long-term consequence of hypertension. It is 
characterized by renal arteriolar thickening and fibrinoid deposition into the glomeruli and 
accompanied by an inflammatory response and proteinuria36. Within the glomeruli, the 
damage results from increased glomerular capillary pressure and permeability. This leads 
to excess protein infiltration through the glomerular capillary wall and its loss in the urine. 
The toxicity of this protein load generates tubular damage, inflammation and scarring37. 
The glomerular capillary wall is exposed to mechanical stress in vivo arising from capillary 
blood pressure and blood flow. Podocytes, consisting of a cell body, major processes and 
foot processes interlinked by slit diaphragms, may experience lateral stretch as capillaries 
dilate in response to increased filtrate flow generated by hypertension38. They are likely to 
play a critical role in bolstering the glomerular capillary walls against hemodynamic 
pressure through their actomyosin based contractile behavior. However, chronically 
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increased mechanical load due to glomerular capillary hypertension (GCH) results in 
irreversible glomerular damage, including podocyte injury, and may alter the elastic 
properties of the glomerular structure39,40. 
Sodium and Chronic Kidney Disease 
Sodium is an essential nutrient necessary for physiological functions including 
maintenance of plasma volume, acid-base balance, transmission of nerve impulses, and 
normal cell function. Data from around the world suggest that average sodium consumption 
is well above that needed for physiological function41.  
A large body of evidence confirms the association between high sodium intake and 
increase in blood pressure and cardiovascular events. High sodium intake also presents a 
challenge for excretion by the kidneys, which is another potential mechanism for affecting 
blood pressure. Increased sodium intake may lead to increased urinary protein excretion 
and may thus increase the rate of deterioration of renal function42. High sodium intake 
among individuals with kidney disease risk factors, such as diabetes, is more likely to 
precipitate hypertension, which speeds up the progression of diabetic kidney disease.  
In many low-salt consuming societies, hypertension incidence is very low, yet when 
members of these societies migrate to an urban environment with high-salt intake, nearly 
a third of them show a significant increase in blood pressure43. Similarly, certain strains of 
rats develop a significant rise in blood pressure when placed on a high-salt diet. Dogs 
developed salt-induced hypertension following renal mass ablation. Moreover, a high-salt 
diet increased stroke and mortality rates in Sprague-Dawley rats even though it did not 
raise blood pressure above that found in rats fed the low-salt diet, indicating increased 
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arterial pressure is not the only factor influencing the development of vascular 
complications. Wild type 129S mice develop glomerulosclerosis when given high sodium 
in drinking water following nephrectomy and administration of deoxycorticosterone44.  
The mechanisms causing changes in blood pressure and kidney function due to high salt 
intake are likely to be similar in animals and humans. Thus, animal models are invaluable 
in the study of human disease pathophysiology. 
Summary 
Chronic kidney diseases have become a major public health problem worldwide 
today reaching epidemic proportions. One potential outcome of CKD is end-stage renal 
disease, requiring costly renal replacement therapy in the form of dialysis or 
transplantation. It is also a major independent risk factor for cardiovascular disease. 
Worldwide, diabetes is the most common cause of CKD followed by hypertension. Despite 
the flood of new information about the kidney disease pathophysiology, there is a need for 
further rigorous research to further elucidate on the disease process and identify new 
therapeutics. Development of sensitive screening tests are also needed in order to detect 
chronic kidney disease early. Nevertheless, public awareness and promoting health dieting 
is also crucially important in combating kidney disease. These measures will ensure 
appropriate and timely institution of proven treatments to halt or reduce progression of 
CKD. 
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Chapter 2: Study Rationale, Hypothesis and Aims 
Introduction 
Hypertension is the second major cause of end-stage renal disease (ESRD) in the 
United States and elsewhere after diabetes1. It is a progressive cardiovascular syndrome 
that can damage various organs including the kidneys, heart, and brain, and lead to 
premature morbidity and death45,46. Patients with pre-existing renal disease and/or diabetes 
exhibit a greatly enhanced susceptibility to accelerated renal damage even with mild-to-
moderate hypertension35. Moreover, subtle target organ damage, including kidney damage 
indicated by microalbuminuria, takes place early in the course of hypertension and can be 
left unrecognized until major complications occur. The kidneys are one of the key organs 
affected in hypertension patients, and the relationship between hypertension and chronic 
kidney disease (CKD) remains perplexing especially with evidence supporting that 
hypertension is both a “cause and effect” of CKD14.  
The kidney glomerulus is a highly specialized structure that is the site of plasma 
ultrafiltration and urine production. The glomerular capillary wall, composed of glomerular 
epithelial cells or podocytes, glomerular basement membrane (GBM), and endothelial 
cells, is exposed to mechanical stress in vivo arising from capillary blood pressure and 
blood flow. Podocytes, consisting of a cell body, major processes and foot processes 
interlinked by slit diaphragms, may experience lateral stretch as capillaries dilate in 
response to increased filtrate flow generated by hypertension (Figure 1). They are likely to 
play a critical role in bolstering the glomerular capillary walls against hemodynamic 
pressure through their actomyosin based contractile behavior. However, chronically 
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increased mechanical load due to glomerular capillary hypertension (GCH) results in 
irreversible glomerular damage, including podocyte injury, and may alter the elastic 
properties of the glomerular structure. Podocyte damage leads to cell hypertrophy, foot 
process effacement, cell body attenuation, cytoplasmic overload with reabsorption 
droplets, and, finally, detachment from the GBM40. Podocyte loss leads to proteinuria and 
progressive loss of kidney function resulting in glomerulosclerosis and ESRD. Thus, 
podocyte injury is critical in the progression of hypertension-associated kidney damage. 
 
 
Figure 1. Illustration of blood pressure forces acting on the glomerular capillary wall. A) Cross section of a 
glomerular capillary under normal pressure (blue arrows). Under these conditions little traction is generated 
by podocyte foot processes to resist wall tension because the intact foot process structure is sufficient to resist 
wall tension passively. B) Glomerular capillary subjected to hypertension. The immediate podocyte response 
is to generate increased traction in order to stiffen the capillary wall and resist deformation due to increased 
wall tension. The podocyte foot processes (C) are arranged around the outer aspect of the capillary wall, and 
are likely to play an important role in resisting these tension forces. D) Sustained glomerular hypertension 
results in podocyte injury, foot process effacement (E), and detachment. 
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Human Kidney Research is Essential, but is it Enough? 
A better understanding is needed of how podocyte injury develops in glomerular 
hypertension. However, insights into these mechanisms, based on our observations in 
human disease, are lacking for a variety of reasons. First of all, many individuals with 
hypertension can remain undiagnosed for a long time, particularly asymptomatic patients 
or those who lack access to healthcare, thus changes occurring in the kidney during this 
asymptomatic period are missed. Complicating the issue, renal biopsies are not routinely 
performed in individuals newly diagnosed with essential hypertension. Moreover, even 
when kidney biopsy is performed, specimen adequacy, especially in focal renal disease, is 
a major consideration with respect of number of glomeruli required for exhaustive genetic 
and pathological evaluation47,48.  
Interval biopsies are key in characterizing disease progression. However, repeating 
the renal biopsy in individual patients is not widely practiced and certainly not in 
uncomplicated cases of essential hypertension48. The potential for confounding by pre-
existing diseases or factors such diabetes, connective tissue disorders, infections, and 
drugs, can be very difficult to control. Such confounding variables make it difficult to 
assess hypertension-specific or mechanically induced glomerular responses. As a result, 
we have little knowledge of the earliest changes in glomerular cell signaling pathway 
activity and gene expression, particularly those changes that precede glomerular 
morphological changes, and the time course of these changes, in response to specific 
glomerular injuries, such as that induced by glomerular hypertension. Yet it is precisely 
these earliest changes that may yield targets for therapeutic intervention, before irreversible 
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damage takes place. Nevertheless, several studies have characterized the glomerular gene 
expression profile in patients with glomerular disease, and animal models of 
glomerulosclerosis49-52. Importantly, because these studies analyzed glomeruli from 
advanced glomerulopathies with histological changes indicative of irreversible glomerular 
scarring, they could not provide much information about the mechanisms of early 
glomerular damage. Thus alternative models of hypertension-associated kidney disease are 
needed to study these early changes.  
 
Mice as a Model of Human Chronic Kidney Disease 
Even though there are compromises associated with any disease model and there 
will never be a perfect model for every disease, different models may be used to study 
different aspects of a given disease. Mouse models in particular bridge the gap between in 
vitro and molecular studies and clinical findings in human disease. Mouse models are 
extensively used in a variety of ways by researchers in academia and the pharmaceutical 
industry, from basic research studies on disease mechanisms to preclinical trials. While not 
perfect, animal models are pivotal to understand disease pathophysiology and to 
developing rational treatment strategies.  
Members of the Mus genus are the primary species used to approximate human 
kidney disease. Historically, rats were a key animal model used to discover many details 
of kidney physiology14,28. This was a result in part of the ability to perform 
microcannulation of nephron segments in these animals. However, recently there has been 
a significant increase in number of studies using mouse models of kidney disease relative 
to rats53. There are many reasons for this exponential rise in use of mouse models of kidney 
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disease. Compared to rats and many other animal models, mice are small in size and can 
be housed in a relatively small space, and therefore are cost effective. Similarly to rats, 
mice have a short generation time and an accelerated lifespan, making the time required to 
perform studies manageable. However perhaps the most important reason for the use of 
mice is the existence of many genetic mouse models of disease (knockout, mutant, 
overexpression, etc) that have been generated, and the relative ease with which new genetic 
models can be created in this species14,28. 
Among the many advantages of murine models is their similarity to humans in 
anatomy, physiology, and genetics. Mice and humans are at least 95% identical at the 
genomic level, making mouse research particularly applicable to human disease and as a 
result, animals have the tendency to be affected by many health problems affecting 
humans54. Structurally, mouse kidneys have a single renal pyramid and are therefore 
termed unipapillate. Otherwise, they closely resemble the human kidney in their structure. 
In the mouse, sexual dimorphism of the glomerular parietal epithelium of Bowman’s 
capsule exists55. The female parietal epithelium cells, similar to humans, are typically 
squamous whereas the male parietal epithelium can be both squamous and cuboidal. The 
mouse kidney consists of approximately 11,000 nephrons compared to 1 million nephrons 
in humans56, yet functionally, both humans and mice have comparable volume handling 
per gram kidney tissue57. 
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Clinically Relevant DOCA-Salt Uninephrectomy Model of CKD 
Substantial effort has been employed toward developing suitable animal models of 
CKD displaying hypertension-associated renal damage comparable to that found in 
humans (Figure 2). Hypertensive renal disease is notable for prominent vascular and 
glomerular injury in the kidney. A number of murine surgical models have been developed 
in the attempt to more closely model the effects of human systemic hypertension on the 
kidney. Foremost among these are models which utilize uninephrectomized animals 
(Figure 2) 53,58-60. The two most widely-used mouse models are: 5/6 nephrectomy and 
DOCA/salt uninephrectomy. The major differnces between these nodels are summarized 
in (Table 2). 
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Figure 2. Mouse models of chronic kidney disease. A) 5/6 nephrectomy (UniNx). This is a two-step 
procedure that involves the surgical removal of one kidney and 2/3 of the other kidney. Mice are given tap 
water and fed regular chow. B) DOCA-salt uninephrectomy. Mice are subjected to uninephrectomy and 
subcutaneous implantation of a timed-release DOCA pellet. Following surgery, mice are given 1% NaCl 
drinking solution. C) Surgical sham. Mice undergo uninephrectomy only to control for the surgical 
intervention and the daily handling of mice. 
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Table 2. Comparison of mouse models of CKD. 
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A clinically relevant model of hypertension-associated renal injury is the 
deoxycorticosterone acetate (DOCA) salt uninephrectomy model. Hypertension in this 
model results from high-salt intake, hypervolemia, and hyperaldosteronism, important 
contributors to hypertension in humans40,61. This model in mice results in a number of 
features of CKD seen in humans, including hypertension, albuminuria, and 
glomerulosclerosis (Figure 3). C57BL/6 and 129S6/SvEv mice are among the most 
commonly used murine strains for disease studies and their genetic background plays an 
important role in their susceptibility to develop progressive glomerulosclerosis in models 
of kidney disease62,63. For instance, when subjected to models of glomerular hypertension, 
severe glomerular damage is observed in mice on a 129S6/SvEv background but not in 
mice on a C57BL/6 background, despite the observation of elevated systemic blood 
pressure in both strains. 
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Figure 3. DOCA-salt uninephrectomy model of hypertension. A) Mice are subjected to uninephrectomy and 
subcutaneous implantation of a timed-release DOCA pellet (Arrow). Following surgery, mice are given 1% 
NaCl drinking solution. B) Tail-cuff measurements of systolic blood pressure in wild-type 129S6/SvEv mice 
show significant increase in systolic blood pressure in response to DOCA salt uninephrectomy. *P<0.01 
statistically significant difference from baseline. C) Right kidney to body weight index (ratio) and heart to 
body weight index (ratio). Mice develop cardiac and renal hypertrophy at 42 days in response to systemic 
hypertension. D) Marked proteinuria as early as 3 days post DOCA-salt uninephrectomy. Urinary albumin 
for first seven days post-operatively is shown by Coomassie blue-stained SDS-PAGE gel. Proteinuria begins 
on day 3 post-operatively and progressively increases. D) Photomicrograph of a glomerulus in a Periodic 
Acid-Schiff-stained kidney section shows evidence of significant glomerular injury in 129S6/SvEv mice at 
42 days post operatively, including segmental sclerosis and epithelial proliferation apparent on the left. 
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Differential Susceptibility to CKD 
There is considerable variability in the susceptibility to systemic hypertension and 
its complications in humans. Epidemiological studies support the premise that there is a 
heritable component that at least partially explains this differential susceptibility64. For 
example, African Americans with hypertension are seven times more likely to develop 
CKD and ESRD than Caucasians1. Recent data suggests that polymorphisms in the genes 
encoding myosin heavy chain 9 (MYH9) and apolipoprotein L1 (APOL1) are associated 
with the increased susceptibility to CKD and ESRD in this population6,65. The genes that 
have been identified suggest a genetically-associated variability in cellular integrity that 
leads to a corresponding variable susceptibility to hypertension-associated tissue damage.  
In an analogous fashion to that in humans, hypertension-induced glomerular 
damage in mice is also strain dependent. As noted above, the damage response to 
hypertension observed in mice on a 129S6/SvEv background subjected to models of 
glomerular hypertension, is not observed in mice on a C57BL/6 background. This finding 
suggests that there are molecular response factors present in the 129S6/SvEv mice but 
absent in C57BL/6 mice that confer susceptibility to glomerular damage in models of 
glomerular hypertension. 
Blood Pressure monitoring in Mouse models of CKD 
Mice and humans have similar levels of systemic blood pressure despite the vast 
difference in size. Part of the explanation for this is that these species have very different 
heart rates. In general, the smaller the organism, the faster the heart rate. The resting heart 
rate of adult mice is 580-680 beats per minute, compared to adult humans at an average 72 
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beats per minute66. There are two general methodologies used to determine blood pressure 
levels in mice: non-invasive and invasive methods. Because of their small size and 
correspondingly small peripheral blood vessels, tail-cuff techniques are the most 
commonly used indirect techniques for obtaining blood pressure in mice. Currently, the 
most commonly used tail-cuff system (Visitech, Apex, NC) is based on 
photoplethysmography, an optically obtained volumetric measurement of organs, and is a 
computer integrated system; it measures blood pressure by automated inflation of the tail-
cuff with the simultaneous photoelectrical monitoring of the oscillation of blood in the 
mouse's tail67.  
Tail-cuff measurements of blood pressure in mice have the advantage that they are 
non-invasive and therefore do not require advanced surgical skills. Importantly, the method 
is valuable for screening and monitoring changes in blood pressure over extended periods 
of time without altering the mouse vascular system or physiology, making it useful for 
long-term serial studies. They are also cost-effective compared to the direct methods and 
are ideal for large-scale and high through-put experiments. One drawback is that this 
method requires a “training period” of several days, in order to acclimate the mice to the 
instrument and to the handling by the operator, and thereby reduce stresses which may 
affect blood pressure measurements. 
Direct monitoring of blood pressure can be performed by a number of different 
techniques including carotid or femoral arterial catheterization, implanted radiotelemetry 
systems, and transducer tipped catheters. These techniques are invasive and therefore are 
associated with higher morbidity and mortality rates68. A major disadvantage of the direct 
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measurement methods are the lofty operating and catheter refurbishment costs. In addition 
to cost, other disadvantages include the need for surgical skills and training, particularly in 
small mice weighing less than 25 grams69. 
Molecular Technologies in Renal Disease: The Microarray Approach 
The development of molecular biological tools has opened new opportunities to 
study the pathophysiology of disease at the molecular level. Gene expression profile 
analysis has been at the forefront of these studies. Microarray technology provides a 
powerful tool for rapid, comprehensive, and quantitative analysis of whole-genome 
expression profiles in tissue samples. This technology involves the application of 
picomolar samples of a large range of DNA probes to a solid substrate, such as silicon or 
glass. Microarrays are printed by high-speed robotics as a high-density array on the 
substrate70. A solution of cDNA prepared from transcribed mRNA is applied to the 
substrate surface, and reacts with the probe samples in the array. Chemiluminescent or 
other detector mechanisms are used to identify the probes which reacted successfully with 
their corresponding cDNA. In this way, mRNA content of an isolated tissue sample may 
be characterized. 
DNA microarrays can profile the whole transcriptome, the expressed genome of a 
species. They provide a practical and economical tool for studying the gene expression of 
a multitude of genes in parallel. Using this tool, in concert with disease model systems, 
new genes and pathways can be identified that are important to the pathophysiology of 
these specific disease processes. Moreover, transcript profiling analysis allows for 
detection of genome-wide differences in the expression level of genes, meaning both 
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identification and detection of differences in the abundance of nearly all mRNA transcripts 
present in the cells of samples at a given point of time. The comprehensive profiling of 
gene expression can provide novel insights into both physiological and pathological 
mechanisms of gene expression regulation.  
In nephrology, the use of oligonucleotide microarray based approaches has led to 
identification of novel diagnostic and prognostic parameters in patients with diverse renal 
diseases or renal transplants71,72. Expression array studies of renal disease have also been 
used to facilitate the prediction of disease course over time by identification of disease 
specific marker profiles, thereby allowing for the segregation of patients with either a 
progressive or a stable disease course73. 
Tissue-specific Gene Expression: Glomerular Isolation 
To study the pathophysiological processes and pathways in hypertension-induced 
glomerular injury, high purity glomerular isolates are key for glomerular-specific gene 
expression profiling. As glomeruli constitute only a small percentage of the total renal 
cortex56, the use of homogenates of total kidney tissue results in a low representation of 
glomerular cells in the sample material and is unsuitable for study of glomerular 
mechanisms in most cases. Due to the high sensitivity of the analytical methods applied 
for transcript profiling analyses, the interpretation of data obtained from investigation of 
total or cortical kidney tissue always inherits the risk of signals actually derived from 
glomerular cells overlaid by stronger signals derived from other kidney cell types. 
Three different methodological principles of glomerulus isolation are 
distinguished: differential sieving techniques, microdissection techniques, and magnetic 
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isolation of glomeruli from kidneys perfused with magnetic particles (Figure 4). These 
methods differ with respect to yield and purity of glomerulus isolates and thus their 
suitability for performance of gene expression analyses. It is very challenging to generate 
glomerular isolates of high purities from murine kidneys by using the graded sieving 
techniques, as mouse glomeruli and fragmented tubules display similar diameters. 
However, magnetic isolation of murine glomeruli from kidneys perfused with iron oxide 
or commercially available spherical superparamagnetic beads, provide high-purity and 
large-scale glomerular isolates (Figure 4C).  
The availability of samples of human kidney tissue is generally limited. Therefore, 
application of glomerular isolation methods to human kidney tissue is usually restricted to 
needle biopsies, using microdissection techniques under a stereo microscope. However, 
laser-capture microdissection can be used on archived renal specimens, formalin-fixed or 
frozen, for RNA extraction using a laser microbeam. This method has the advantage of 
high precision; however, the amount of glomeruli obtained is relatively low. 
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Figure 4. Schematic overview of glomerular isolation process. A) Principle of glomerular isolation using iron 
oxide particles or magnetic spherical beads. The perfused particles embolize to the glomerular capillary tuft 
and are trapped in the glomerular microvasculature. B) Procedure for glomerular isolation using iron oxide. 
Anaesthetized animals are perfused through the left ventricle with iron oxide suspension and the right atrium 
is cut to maintain an open circulation. Kidneys are harvested and minced into ~1mm³ pieces. The tissue is 
then digested with collagenase A at 37°C for 30 minutes and then gently homogenized through a 100 μm cell 
strainer with 60 ml PBS. Glomeruli containing iron oxide particles are isolated with a magnetic particle 
concentrator. For enhanced purity, magnetic glomerular isolation is repeated up to three times and the isolated 
glomeruli are suspended in 2ml PBS. C) Kidney cross section (right) showing vasculature and glomeruli 
perfused with dark-appearing iron oxide. The glomeruli appear as small black dots due to entrapped iron 
oxide. Middle and left images show high-purity isolated glomeruli. 
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Study Rationale 
The foregoing highlights two major frontiers in our understanding of hypertension-
associated glomerular damage: (1) the earliest cellular responses to glomerular capillary 
hypertension, and (2) genetic variability in that response. For this study, we propose to 
utilize microarray gene expression analysis of isolated glomeruli from hypertensive 
C57BL/6 and 129S6/SvEv mice, in order to find the genes that are strongly associated with 
hypertension-induced glomerular injury in 129S6/SvEv mice, and the absence of injury in 
C57BL/6 mice (Figure 5). We will examine gene expression changes at different time 
points, including the early time points with no apparent histological changes, in order to 
identify the initial cellular response to glomerular capillary hypertension. From these 
experiments, we will identify a limited set of key genetic targets for further in vitro study. 
The increased understanding of the molecular mechanisms underlying hypertension-
associated podocyte injury and glomerular damage which will result from these studies, 
will hopefully lead to identification of novel pharmacologic targets or therapeutic strategies 
for patients with hypertension and renal disease.  
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Figure 5. Experimental Design Overview. Hypertension is induced in C57BL/6 and 129S6/SvEv male mice 
using the DOCA-salt uninephrectomy model. Following intervention, glomeruli are isolated at 0, 1, 7 and 42 
days for RNA extraction. Using microarray technology, differentially expressed glomerular transcripts 
(C57BL/6 vs. 129S6/SvEv) are identified. Bioinformatical analysis is performed to identify molecular 
pathways involved in glomerular injury at different stages of the process. 
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Hypothesis and Aims 
Hypothesis 1: The glomerular damage that develops in association with glomerular 
capillary hypertension is preceded by changes in gene expression in glomerular cells 
involving molecular signaling pathways associated with cell proliferation, adhesion, and 
injury protection.  
Hypothesis 2: The difference in response between 129S6/SvEv and C57BL/6 mice 
subjected to models of glomerular hypertension corresponds to differences in early gene 
expression changes, particularly in genes with known roles in glomerular function, cell 
mechanical behavior, cell proliferation, adhesion, and injury protection.  
To address these hypotheses, I will accomplish the following: 
Aim 1: Identify molecular pathways exhibiting early changes in gene expression and that 
precede GCH-associated glomerular injury, focusing on pathways related to glomerular 
function, cell mechanical behavior, cell proliferation, adhesion, and injury protection. 
Identify genes that are differentially expressed in glomeruli in 129S6/SvEv and C57BL/6 
mice under normal physiological conditions, and under GCH conditions, that confer 
susceptibility to GCH-associated glomerular injury in 129S6/SvEv mice and protection 
from injury in C57BL/6 mice.  
Aim 2: Identify candidate genes that exhibit a differential response to GCH in 129S6/SvEv 
and C57BL/6 mice, and that are most likely to be involved in podocyte injury and 
glomerular damage. Confirm that the targeted genes/pathways are (a) expressed in cultured 
glomerular cells and (b) exhibit altered expression when cultured cells are subjected to 
stress. 
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Approach 
1) Develop a murine model of glomerular hypertension using the deoxycorticosterone 
acetate (DOCA) salt uninephrectomy model. Induce systemic hypertension in 129S6/SvEv 
and C57BL/6 using the DOCA salt uninephrectomy model. 
2) Measure the systolic blood pressure of mice after initiation of DOCA salt 
uninephrectomy to confirm effectiveness of the surgical intervention.  
3) Develop a reproducible, efficient, and inexpensive method of obtaining high-purity 
glomerular isolates. Isolate glomeruli at different time points after initiation of the DOCA 
salt uninephrectomy model for analysis of gene expression, and for other studies.  
4) Extract glomerular RNA from DOCA salt uninephrectomized-mice at different time-
points.  
5) Use microarray technology and data mining tools to identify the early molecular changes 
in glomerular cells that are specific to increased glomerular hemodynamic stress.  
6) Validate the findings in 5 using new samples from mice that undergo DOCA salt 
uninephrectomy. This will confirm universality of the results generated from the 
microarray analysis. Immunohistochemistry will be used for validation.  
7) Perform a DOCA assay on primary glomerular cells to rule out the direct effect of DOCA 
on identified molecular targets and confirm altered changes are induced by upstream 
effectors. 
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Chapter 3: Methods, Results, and Discussion 
Methods 
DOCA Salt Uninephrectomy Model of Systemic Hypertension.  
Wild type 129S6/SvEv and C57BL/6 male mice (11-13 weeks) were subjected to 
left uninephrectomy and implantation of a 60 day release pellet containing 150mg 
deoxycorticosterone acetate (DOCA) (Innovative Research of America, Sarasota, FL). The 
mice were given 1% NaCl solution beginning immediately post operatively and fed 
standard chow (Figure 3A). Animals were euthanized at three time points post operatively: 
1 day, 7 days, and 42 days. A subset of animals were prepared for surgery identically to 
the other specimens but euthanized immediately (0 day controls)34. At all time points, spot 
urine was collected for analysis of urine protein. Systolic blood pressure (SBP) was 
measured indirectly by the tail cuff method (BP-2000, Visitech Systems). Mice were 
trained for a minimum 3 days to reduce the stress associated with blood pressure 
measurements. Measurements were taken in a quiet room in the mornings a minimum 3 
times a week for 6 weeks and two sets of 10 measurements were taken each session. At 
least 6 out of 10 measurements were required to be validated by the acquisition software 
to accept each measurement. 
Large-Scale High-Purity Glomerular Isolation.  
Glomeruli will were isolated using the iron oxide method as previously described74 
with some modification providing large scale high-purity glomerular samples for protein 
and gene expression analysis (Figure 4). Briefly, anaesthetized animals were infused 
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through the left ventricle with iron oxide diluted in phosphate buffered saline (PBS). Prior 
to infusion, the right atrium was cut to maintain an open circulation. Immediately after iron 
oxide infusion, kidneys were harvested, dissected, minced into approximately 1 mm3 
pieces and digested in collagenase A (1 mg/ml) (Roach) at 37 °C for 30 minutes. The 
kidney tissue was gently passed through a 100 μm cell strainer (BD Biosciences, San Jose, 
California) with 60 ml PBS. Glomeruli containing iron oxide particles were isolated with 
a magnetic particle concentrator (Figure 4). For enhanced purity, magnetic glomerular 
isolation was repeated up to three times. The isolated glomeruli were centrifuged, 
suspended in 2ml PBS, snap frozen, and stored at -80 for later use. 
Kidney Histology and Electron Microscopy 
Pieces from the middle portion of harvested kidneys were cut and fixed in 10% 
buffered neutral formalin (NBF) immediately at the time of harvest. The cut sections were 
2-3 mm in thickness and left in fixative overnight to ensure penetration. After the tissue 
was fixed, it was processed using a series of increasing concentrations of alcohol followed 
by clearing using xylene. Then the tissue was manually embedded in paraffin blocks to 
ensure proper alignment. Kidney sections (5 μm thick) were cut using standard microtomy 
procedures, and sections were stained with hematoxylin and eosin (H&E) and periodic 
acid–Schiff (PAS) for general pathological evaluation.  
For electron microscopy, small 1 mm3 kidney pieces from the mid-section of the 
kidney were fixed in 3% glutaraldehyde-based fixative overnight at 4 °C. The tissue was 
post-fixed in 1% osmium tetroxide, dehydrated in graded acetone, and embedded in epoxy 
resin. Using an ultra-microtome (Leica UC7 microtome), semi-thin sections (2 μm thick) 
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were cut using a glass knife and stained with toluidine blue dye. Non-lesional glomeruli 
were identified in semi-thin sections and the tissue blocks were further trimmed (Figure 6). 
Ultra-thin sections (0.1 μm thick) were stained with 4% aqueous uranyl acetate and 0.4% 
lead citrate. Tissue grids were examined with a transmission electron microscope (Jeol 
JEM-1011, Japan), and detailed images of the glomeruli were taken with a digital camera 
system (Gatan Erlangshen ES1000W). 
 
 
Figure 6. Electron microscopy of murine kidney. To the left, a semi-thin kidney section stained with 
toluidine blue dye shows two non-lesional glomeruli at the light microscopy level. One glomerulus is selected 
for further evaluation. To the right, the same glomerulus at low magnification (1500x) examined under the 
electron microscope. Higher magnification allows examination of ultrastructural changes. 
 
Glomerular Stiffness measurements. 
In order to characterize the stiffness of whole, isolated glomeruli, a technique 
referred to as microindentation was utilized. This assay for whole glomeruli uses a 
microscope stage that is moved in 160 nm increments to compress a single glomerulus 
against a probe that measures nano-Newton (nN) forces75. As the glomerulus is 
compressed, the force required for the compression is measured, and a force – deformation 
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relationship is established. The stage is then lowered using the same steps, and the amount 
of elastic recovery determined. These measurements are used to derive the glomerular 
elastic moduli. For these studies, a small superficial portion of kidney tissue (about 4 mm3) 
was harvested from anesthetized mice immediately before iron oxide perfusion, and 
glomeruli were isolated from this sample. This was done in order to ensure that iron oxide 
particles did not interfere with glomerular mechanical properties. 
Gene Expression Analysis 
Measurements of RNA quantity and quality, RNA amplification and biotin 
labelling for preparation of cDNA for gene expression analysis and the array experiments 
(target preparation, hybridization and scan of chips) were performed by the Boston 
University Microarray Core facility according to the manufacturer’s instructions, as 
described in the respective protocols. Briefly, identical amounts of high quality glomerular 
RNA were reverse transcribed into cDNA, amplified, fragmented and labelled with biotin. 
After target preparation for GeneChip® Analysis, each sample was hybridized to a 
GeneChip® Mouse Gene 2.0 ST Array (Affymetrix, USA) (Figure 7). Then the arrays were 
washed, subsequently stained with phycoerythrin-conjugated streptavidin (SAPE) and 
washed again. The fluorescent intensity emitted by the labelled targets was measured by 
an Affymetrix GeneChip Scanner. Scanned hybridization images were translated into so-
called “.CEL files” (Affymetrix© Microarray Suite version). Each .CEL-file contains the 
average signal intensity of all pixels within the designated region corresponding to each 
probe on the Affymetrix © GeneChip Array. After GeneChip scanning, the efficiency of 
hybridization, as well as the quality of hybridized targets were evaluated. For identification 
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of differentially expressed transcripts in samples derived from the different time points in 
both strains, (.CEL file) data were analyzed using the R Bioconductor software76. 
 
 
Figure 7. Affymetrix Microarray Workflow Overview. Total RNA was isolated from glomerular isolates, 
and quality and quantity of total RNA were measured. From the total RNA, mRNA is reverse transcribed 
into cDNA which is then transcribed into cRNA. The cRNA is then amplificated, fragmented and 
biotynilated. The biotinylated cRNA fragments hybridize to GeneChip® Mouse Gene 2.0 ST Array. A laser 
scanner determines the amount of bound biotinylated cRNA indirectly through the streptavidin-conjugated 
phycoerythrin fluorescence at each feature (probe-specific region) within a probe set. Bioinformatical 
analysis was performed, using software tools including R Bioconductor and Ingenuity Pathway analysis. 
Figure adapted from affymetrix.com.  
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Normalization and Quality Assessment.  
The arrays were normalized together using the Robust Multiarray Average (RMA) 
algorithm and a CDF (Chip Definition File) that maps the probes on the array to unique 
Entrez Gene identifiers. The technical quality of the arrays was assessed by two quality 
metrics: Relative Log Expression (RLE) and Normalized Unscaled Standard Error 
(NUSE). For each sample, median RLE values > 0.1 or NUSE values > 1.05 are considered 
out of the usual limits, although RLE is the quality metric most strongly associated with 
technical quality. All arrays had median RLE and NUSE values well within these limits.  
Positive Control Gene Expression.  
The expression of several sex-specific genes (Xist, Ddx3y, Eif2s3y, Kdm5d, and 
Uty) was assessed to estimate the dynamic range of the array, as the female-specific marker 
Xist and constitutively expressed Y-linked genes serve as strong positive and negative 
expression controls in females, respectively (and vice versa in males). The expression of 
the Y-linked genes was high (~5-7.5 log2 units) levels in all samples. Conversely, the 
expression of Xist was at very low levels (~2 log2 units) in all samples. This indicates that 
all animals were male and that the experiment has good dynamic range to identify genes 
with true differential expression. 
Principal component analysis  
Principal component analysis (PCA) is a mathematical algorithm that reduces the 
dimensionality of the data while retaining most of the variation in the data set. PCA is a 
multivariate technique that analyzes a data table in which observations are described by 
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several inter-correlated quantitative dependent variables77. Its goal is to extract the 
important information from the table, to represent it as a set of new orthogonal variables 
called principal components, and to display the pattern of similarity of the observations 
and of the variables as points in maps. PCA was performed using the R Bioconductor 
software76. 
Pathway and Functional Analyses.  
Pathway and functional analyses of the differentially expressed genes were 
performed using the commercially available systems biology-oriented software package 
Ingenuity Pathway Analysis (IPA) (Qiagen). The knowledge base utilized by this software 
contains information on human, mouse, and rat genes, including annotations, synonyms, 
and over 1.4 million published biological interactions. Thus, this knowledge base provides 
a framework by which the pattern of differential gene expression identified by large 
microarray experiments can be annotated in terms of functional relationships in order to 
understand the underlying biological mechanisms. For each pathway, a statistical 
parameter (“P” value) is calculated which indicates the goodness of fit of the user's data to 
IPA databases. The parameter (−log P value) is calculated using Fisher's exact test and 
indicates the likelihood that a gene will be found in a network due to random chance. This 
is accomplished by also considering the total number of functions/pathways/lists of eligible 
genes in the data set, and the reference set of genes (those which potentially could be 
significant in the data set). In case of interactive networks, all the identified genes are 
mapped to genetic networks available in the Ingenuity database and are ranked by the score. 
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For example, if a network achieves a score of 2, it has at least 99% confidence of not being 
generated by chance alone.  
Gene Ontology(GO) Enrichment Analysis. 
Genes were assigned to broad GO terms using the GO Term Mapper 
(http://go.princeton.edu/cgi-bin/GOTermMapper), yielding both the percentage of 
submitted genes attributed to a given GO term versus the percentage of all annotated genes 
attributed to that GO term. Relative overrepresentation was calculated by dividing the 
percentage of submitted genes attributed to a GO term by the percentage of all available 
genes annotated with this GO term. Enrichment was considered significant if P was less 
than 0.05. The GO provides a structure that organizes genes into biologically related groups 
according to three different criteria78. It classifies genes and their products due to either the 
biological process in which they are acting, the molecular function they are able to conduct 
or the cellular component where they can be found. Each gene can be described (annotated 
with) multiple terms. It provides a system for hierarchically classifying genes or gene 
products to terms organized in a graph structure called an ontology78,79. 
Validation of the Microarray Data by Immunohistochemistry. 
To confirm the expression and distribution of the differentially expressed candidate 
genes, immunofluorescence histochemistry was used. Briefly, tissue sections were baked 
and deparaffinized using standard protocols. Antigen retrieval was performed using 0.01 
M sodium citrate buffer (pH 6.0) with microwave heating (EZ-Retriever, BioGenex) at 
95°C for 20 minutes. Protein blocking was performed at room temperature for one hour. 
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After tissue blocking, the following primary antibodies (Table 3), incubated overnight 
(4°C), were used for immunostaining. 
After overnight primary antibody incubation, secondary antibodies with conjugated 
to Cy2 or Cy3 were incubated for 30 minutes at room tempreture. A nuclear stain, DAPI 
was also used. 
 
Table 3 List of antibodies used and their dilutions. 
The perfused kidneys were transversely sectioned at the level of the hilum in a 
standard manner. The tissue was fixed in 10% formalin for 1 day at 4 °C and embedded in 
paraffin. Five micrometer thick sections were stained with H&E and PAS for histological 
evaluation. Tissue was examined in a blind manner. 
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Results: 
Blood Pressure Changes 
Systemic hypertension is associated with changes in glomerular hemodynamics and 
progressive glomerular damage. Intriguingly, the species and strain dependent severity of 
hypertension-induced glomerular damage is potentially modulated by genetic factors59,80. 
Here, we utilized a clinically relevant model of systemic hypertension, DOCA/salt 
uninephrectomy, to examine the effect of hypertension on the glomeruli of the most 
commonly used inbred mice strains, 129S6/SvEv and C57BL/6. To begin this analysis, we 
first characterized the systemic blood pressure changes that resulted with this model, in 
part to determine if these changes were also species dependent. 
Within seven days of intervention, both stains showed a significant increase in 
systolic BP compared to baseline (P=0.01). Figure 8 shows the time-course changes of 
systolic BP. The BP was consistently elevated in both strains as early as day 3 of 
intervention. Blood pressure measurements were not performed earlier than day 3 in order 
to optimize the post-operative recovery of these mice. Sham mice did not show a significant 
change in their systolic pressure (data not shown). 
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Figure 8. To demonstrate that both mice strains developed persistent hypertension in response to the 
intervention, systolic blood pressures were recorded at least 5 days a week, 10–20 measurements each day. 
Systolic blood pressure was measured indirectly by tail-cuff measurements (BP-2000, Visitech Systems). 
Each SBP data point is an average of one day measurements. The measurements were performed by the same 
operator at the same time each day in the same room. Systolic blood pressure is significantly increased in 
both wild type 129S6/SvEv and C57BL/6 mice following DOCA/salt uninephrectomy treatment. 
 
 
 
 
 
 
 
 
 
  
44 
Glomerular Lesions and Podocyte Loss 
Kidneys 1 day and 7 days post DOCA salt uninephrectomy showed no significant 
pathologic changes in glomeruli, tubulointerstitium, or vasculature in either 129S6/SvEv 
or C57BL/6 strains, which was comparable to untreated kidneys (0 days). However, at 42 
days, the extent of glomerular damage in 129S6/SvEv mice was significant in comparison 
to C57BL/6 mice and to baseline ( Figure 9). At 42 days, the 129S6/SvEv mice exhibited 
heterogeneous glomerular lesions including focal global and segmental 
glomerulosclerosis; with or without evidence of epithelial proliferation ( Figure 9B). These 
lesions affected mainly the juxtamedullary glomeruli. In addition, the lesional kidneys 
showed numerous tubular microcysts and PAS+ casts, and focal tubular epithelial protein 
reabsorption. Ultrastructurally, by day 42, the non-lesional glomeruli in the 129S6/SvEv 
kidneys reveal segmental podocyte foot process effacement, microvillous transformation 
of podocytes, and increased foot process irregularity compared to the C57BL/6 mice at 42 
days, and earlier time points in both strains (Figure 10). Hypertension in humans is known 
to induce podocyte injury and loss81,82. Consistent with this observation, by day 42 both 
strains showed a significant reduction in WT-1 positive glomerular cells compared to their 
baselines (day 0). However, the podocyte loss in the 129S mice was more severe compared 
to C57BL/6 mice (Figure 11). 
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Figure 9. Glomerular injury in response to DOCA-salt uninephrectomy. A) Images from Periodic acid-
Schiff (PAS) kidney sections iGlomeruli at 1 day and 7 days post DOCA salt uninephrectomy show no 
significant pathologic changes, relative to glomeruli in untreated kidneys (0 days). However, at 42 days there 
is evidence of significant glomerular injury in 129S6/SvEv mice, including segmental sclerosis, whereas 
C57BL/6 mice continued to show no significant glomerular injury. A hyaline cast is also apparent at 42 days 
in the 129S6/SvEv mouse. B) Periodic acid-Schiff (PAS) kidney sections in the 129S6/SvEv mice exhibit 
heterogeneous glomerular lesions involving mainly the juxtamedullary glomeruli. These lesions include 
global and segmental glomerulosclerosis; with or without evidence of epithelial proliferation. Other 
glomeruli showed global or segmental proliferation without evidence of sclerosis. The kidneys in the 
129S6/SvEv mice also showed numerous tubular microcysts and PAS+ casts, and focal tubular epithelial 
protein reabsorption. Significant tubular epithelium atrophy is also observed.  
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Figure 10. Podocyte foot process effacement in 129S6/SvEv mice. Transmission electron microscopy was 
performed on kidneys from 129S6/SvEv and C57BL/6 mice including controls (0 days) and 1, 7, and 42 days 
post-DOCA-salt uninephrectomy. In C57BL/6 mice at all time points, and in 129S mice at 1 and 7 days, 
glomerular capillaries appear normal, with expected podocyte foot process structure, uniform GBM 
thickness, and endothelial cells with normal fenestrations. However, in 129S mice at 42 days post-
operatively, glomerular capillaries in non-lesional glomeruli reveal segmentally prominent podocyte foot 
process effacement (arrow), as well as thickening and irregularity of the glomerular basement membrane and 
focal podocyte detachment.  
 
Figure 11. Glomerular podocyte number is reduced after DOCA-salt uninephrectomy. A) 
Representative images of WT-1, DAPI, and podocin immunofluorescence staining of kidney glomeruli. WT-
1 is a podocyte-specific nuclear marker. Podocin was used to identify glomerular tuft. B) Results of 
morphometric data indicating number of WT1-positive cells identified per glomerular cross-section in 129S 
(n=3) and C57BL/6 (n=3) mice. A minimum of 50 glomeruli were examined per mouse. 129S6/SvEv exhibit 
marked podocyte loss at 42 days compared to C57BL/6 mice. *P<0.05. 
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Glomerular Stiffness 
Very little information is known about the mechanical properties of glomeruli and 
their response to hemodynamic forces induced by hypertension. Glomerular mechanical 
properties, particularly stiffness, may be an indicator of structural integrity of glomeruli 
and may be an indicator of glomerular susceptibility to hemodynamically-induced injury. 
Here we measured the stiffness of the glomeruli, expressed as elastic modulus, to determine 
how it changes over time. In the 129S mice, the variation between time points was much 
greater; there was transient decrease in the elastic modulus at day 1 post-operatively, 
followed by a dramatic increase in elastic modulus at day 7 which was statistically 
significant compared to C57BL/6 mice (P= <0.05). By day 42 the stiffness reduced to near 
baseline (Figure 12).  
 
Figure 12. Glomerular stiffness measurements. Stiffness of the glomeruli (expressed as elastic modulus) and 
its changes over time after initiation of DOCA-salt uninephrectomy treatment were measured in 129S and 
C57BL/6 glomeruli perfused with buffer only at time of tissue harvest and glomerular isolation. C57BL/6 
glomeruli (blue) showed little variation in elastic modulus over the 42 day period examined. In the 129S mice 
(red), changes were much more pronounced; there was transient decrease in the elastic modulus at day 1 
followed by a dramatic increase at day 7 (P= <0.05) and by day 42 the stiffness reduced to near baseline. At 
least 4 glomeruli were measured from each of 3 mice at each time point. 
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Glomerular Gene Expression Profiling 
The primary objective of this study is to characterize the glomerular transcriptional 
response to systemic hypertension and associated hemodynamic forces in the glomerulus. 
The approach taken here utilizes a mouse strain that is susceptible to severe glomerular 
injury (129S), and a relatively resistant mouse strain (C57BL/6), to identify genes 
specifically associated with the development of hypertension-associated glomerular injury. 
Based on the strain’s phenotype in response to hypertension, we have hypothesized that 
differentially expressed genes in the C57BL/6 mice confer protection to hemodynamic 
stress while the differentially expressed genes in the 129S mice confers susceptibility to 
glomerular injury. To test this hypothesis, we compared the global gene expression changes 
in the glomeruli of the C57BL/6 and 129S mice after induction of hypertension.  
After subjecting C57BL/6 and 129S mice to the DOCA-salt uninephrectomy model 
of systemic hypertension, high purity glomerular isolates were prepared and used for 
comparative transcriptome profiling using Affymetric microarray MoGenechip 2.0 ST. 
Three replicates of each strain were used for analysis at each of the following time points: 
day 0 (baseline control), and days 1, 7, and 42 post-operatively, in order to study the 
temporal glomerular response to hemodynamic stress.  
 
First, we performed principal component analysis (PCA), to determine if the 
observed variation was attributable to strain, time-effect, or the interaction of the two. We 
found that the samples separated primarily based on strain along the PC1 axis, indicating 
that the greatest variation in gene expression was linked to strain (Figure 13A). Within 
each strain, the day 0 samples separated well from the other time points along the PC2 axis, 
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indicating that the hemodynamic stress caused significant changes in gene expression over 
time. Moreover, the greatest separation was observed between day 0 and day 1 for both 
strains (Figure 13A). This strong initial effect stabilized over the course of the study, 
although this initial separation was stronger in the 129S6/SvEv animals than in the 
C57BL/6 animals.   
Next, in order to explore the dynamics of global gene expression in response to 
hemodynamic stress in mice glomeruli, we compared the transcriptomes of C57BL/6 with 
129S6/SvEv glomeruli, and genes were identified that statistically increased or decreased 
(P=0.05) at least two-fold after hypertension challenge. The results of this analysis are 
illustrated using Venn diagrams in Figure 12C. The pattern of gene expression variation 
across the three time points was strikingly different between the two strains, underscoring 
the genetic diversity between the strains and their distinct responses to hemodynamic stres 
(Figure 13B). The variability in gene expression pattern across the strains at the three time 
points was strikingly different, affirming the large genetic diversity between the strains and 
their responses to hemodynamic stress (Figure 13C). 
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Figure 13. Microarray analysis of global gene expression in C57BL/6 and 129S6/SvEv glomeruli. A) 
Principal Component Analysis. The samples separated primarily on the basis of strain along the PC1 axis 
(which explains the most variance in the experiment). Within each strain, the strongest separation was 
between days 0 and 1. There is a strong initial effect that stabilized over the course of the study, although this 
separation was stronger in the 129S6/SvEv animals than in the C57BL/6 animals. B) C57BL/6 and 
129S6/SvEv glomeruli have distinctly different transcriptomes at baseline. Heatmap showing log2 expression 
of glomerular genes at baseline prior to any intervention. The genes shown are the top 20 genes exhibiting 
greatest difference exhibit at least two-fold difference between C57BL/6 and 129S6/SvEv strains. The data 
is presented in a matrix format: each row represents a single gene, and each column represents a single 
experimental animal. Red indicates higher expression and blue indicates lower expression. Color saturation 
reflects the magnitude of the ratio relative to the median. C) Comparison of differentially expressed genes of 
glomerular transcriptome in C57BL/6 and 129S6/SvEv mice in response to hypertension. Venn diagrams 
show, at each time point, the number of genes that are upregulated and downregulated at least two-fold 
relative to baseline, uniquely for each strain, and in common between both strains.  
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  We compared the transcriptomes of C57BL/6 and 129S6/SvEv glomeruli at 
baseline, prior to surgical intervention (day 0). The two murine strains exhibit distinct 
transcript profiles at baseline, with 47 and 127 differentially expressed transcripts ((False 
Discovery Rate (FDR) <0.05 and Fold Change (FC) >2)) in 129S6/SvEv and C57BL/6 
strains, respectively. Figure 13B shows the top twenty genes for each strain (40 genes total) 
with respect to the magnitude of the difference in expression between the two strains 
(Figure 13B). Gene-ontology (GO) enrichment analysis of the genes differentially 
expressed in the C57BL/6 at baseline revealed significant enrichment of immune and 
defense response genes (Table 4A), while the 129S6/SvEv mice revealed significant 
enrichment of lipid and small molecule metabolic processes at baseline (Table 4B). This 
baseline difference in glomerular transcriptome could explain, in part, the difference in 
phenotype in models of kidney disease. 
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Table 4. Gene-ontology (GO) enrichment analysis of baseline glomerular genes in 129S6/SvEv and 
C57BL/6 mice. 
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Next, we performed hierarchical gene cluster analysis to investigate the dynamics 
of transcription variation. Genes were ranked by time effect, (P <0.05) among each strain 
(Figure 14). The variability in gene expression across the strains at the three time points 
was strikingly different. The analysis identified a cluster of genes that were upregulated in 
C57BL/6 at days 7 and 42, but not in the 129S mice. This cluster encompassed most of the 
top upregulated genes in the C57BL/6 mice including the fibrinogen chains alpha, beta, 
and gamma, the Serpina genes 3n and 10, Spp1 (encoding osteopontin), Lcn2 (encoding 
NGAL), and Havcr1 (also known as Kim-1). In contrast, a set of genes that were commonly 
upregulated across all the time points in the 129S mice included Ptrpv, one of the top 
upregulated genes in this strain. 
 
 
 
  
54 
 
Figure 14. Hierarchical cluster analysis. Hierarchical clustering of glomerular transcripts that are significantly up- or 
downregulated (P < 0.05) in both 129S6/SvEv and C57BL/6 mice following induction of systemic hypertension. The 
probes are grouped into 8 distinct clusters (labeled 1-8) in 129S6/SvEv mice (A) and into 6 clusters (labeled 1-6) in the 
C57BL/6 mice (B) based on their expression patterns. Each row corresponds to a single probe set (gene), and each column 
represents a time point assayed in triplicate. The colors are scaled so that red and blue indicate z-scores of ≥ 2 or ≤ -2, 
respectively, and white indicates a z-score of 0. Blue represents decreased expression, and red represents increased 
expression. Yellow highlighting indicates top upregulated genes in each strain that were distinctly upregulated in one 
strain but not the other.  
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Ingenuity Pathway Analysis (IPA) identified the top canonical pathways that 
statistically and significantly enriched the set of modulated genes (Figure 15A). The 
identified pathways were ranked in order of increasing Z-scores. A Z-score reflects how 
many standard deviations above or below the population mean a raw score is83. A Z-score 
of 0 means the score is the same as the mean. A positive Z-score implies potential activation 
and a negative Z-score indicates potential inhibition of a pathway. In other words, a high 
Z-score indicates that a pathway has more genes that met the pass criterion than would be 
expected by chance76,84. Remarkably, the genes with the most dramatic upregulation in 
C57BL/6 compared to 129S6/SvEv mice, nearly all belonged to the “Acute Phase 
Response Signaling” pathway (Figure 14B). Based on the pathway’s Z-score, it was 
activated as early as 1 day in C57BL/6, and was activated only later in the 129S6/SvEv 
mice and was associated with a lower Z-score. The Z-score for each time point is depicted 
in (Figure 15A) and the gene components of the same pathway with their fold changes are 
shown in (Figure 15B). Additionally, we performed functional annotation and enrichment 
analysis of the differentially expressed genes at each time point in each strain to delineate 
their role in glomerular disease. 
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Figure 15. Pathway Analysis. A) Top canonical pathways identified by Ingenuity Pathway Analysis (IPA) 
enriched by genes that were differentially expressed following DOCA salt uninephrectomy. Statistical 
significance was determined by using Fisher's exact test (P < 0.05). Graph also shows the Z-scores of the 
each of the top pathways in both strains at each time point. B) The graph shows the Acute Phase Response 
Signaling pathway downstream genes and their respective fold-change, comparing C57BL/6 with 
129S6/SvEv at all time points. Components of the Acute Phase Response Signaling pathway were activated 
as early as day 1 in C57BL/6 mice and only by day 42 in the 129S6/SvEv mice 
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Validation of Microarray Findings 
To validate the microarray results, the top induced candidate genes that are strain 
and time dependent were tested at the protein level using immunohistochemistry (IHC). 
Specifically, double immunofluorescence was used to confirm the relative expression of 
candidate genes for the following reasons: First, the glomerulus has complex structure and 
is made of many different cell types. In order to confirm precisely the cell type with the 
enhanced expression of gene candidates, double immunofluorescence was used with an 
additional cell-specific marker. Furthermore, podocyte injury is considered a hallmark of 
proteinuric kidney disease such focal segmental glomerulosclerosis (FSGS) and diabetic 
nephropathy85,86; therefore, we focused specifically on the podocyte using podocyte-
specific markers, in order to elucidate the role of the podocyte in the glomerular response 
to hypertension-induced injury. Another reason for validating the findings at the protein 
level is that a gene's mRNA level often does not correspond to it’s protein level87. 
Upregulation of Fibrinogen Chain Expression in C57BL/6 Mice 
As described above, Ingenuity Pathway Analysis indicated that group of genes 
associated with the Acute Phase Response signaling pathway was the top canonical 
pathway-associated gene group activated in glomeruli of C57BL/6 mice by the 
hypertension model. This group includes Fga, Fgb, and Fgg, encoding fibrinogen chains 
alpha, beta, and gamma, respectively, which are downstream effectors of the pathway. 
Therefore the expression of fibrinogen beta and gamma chains was evaluated by IHC. 
Immunofluorescence microscopy showed evidence of increased expression of these 
proteins within the glomeruli of C57BL/6 mice compared to the 129S6/SvEv mice (Figure 
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16). The expression was found to be predominatly in podocytes when colocalized with a 
podocyte specific marker, synaptopodin (Figure 16B). 
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Figure 16. Glomerular fibrinongen chain expression in 129S6/SvEv and C57BL/6 mice subjected to 
DOCA-salt uninephrectomy, examined using immunofluorescence microscopy. Representative 
immunofluorescence stainings for fibrinogens γ and β at baseline (day 0) and at 1, 7, and 42 days following 
DOCA-salt uninephrectomy. (A and B) Glomeruli of C57BL/6 mice display evidence of expression of 
fibrinogen chain γ (green) in response to systemic hypertension, whereas 129S6/SvEv mice do not. 
Immunostaining exhibits a punctate intracellular pattern colocalized with podocytes co-immunostained for 
synaptopodin (SYNP, red) that is strongest at 42 days. There is background tubular epithelial reactivity for 
fibrinogen-γ at all time points in both strains. (C) Quantification of fibrinogen-γ expression at day 42 post 
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DOCA/salt uninephrectomy reveals a significant increase in immunoreactivity in C57BL/6 relative to 
129S6/SvEv mice. Data are presented as mean value (±) SE. * P < 0.005. (D) fibrinogen-β immunoreactivity 
(red) is also significantly increased in glomeruli of C57BL/6 mice at day 42 but not in 129S mice. Fibrinogen-
β immunoreactivity is punctate and segmentally distributed, and is again evident in podocyte cell bodies. 
Background tubular epithelial reactivity for fibrinogen-β is evident at all time points in both strains. (E) 
Quantification of fibrinogen-β expression at day 42 post DOCA/ salt uninephrectomy shows a significant 
increase in immunoreactivity in C57BL/6 relative to 129S6/SvEv mice. Data are presented as mean value (±) 
SE. * P < 0.005.  
 
Upregulation of Glomerular Serpina3 Expression in C57BL/6 Mice 
Similar to the fibrinogen chains, Serine Protease Inhibitor A3 (serpina3) is a 
downstream product of the Acute Phase Response Signaling pathway. The gene encoding 
Serpina3 was also found to be among the genes most significantly induced in C57BL/6 
mice upon institution of the hypertension model. Therefore we also investigated glomerular 
Serpina3 protein expression in mice subjected to the DOCA-salt uninephrectomy 
hypertension model. The change in expression of Serpina3 protein at all time points is 
depicted in (Figure 17) and its expression has been validated using IHC. Immunocostaining 
of Serpina3 with podocyte-specific marker synaptopodin (SYNP) displayed increased 
expression in podocytes (Figure 17B). Co-immunostaining for Serpina3 protein with 
podocyte-specific marker synaptopodin (SYNP) revealed increased expression of Serpina3 
protein in podocytes. 
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Figure 17. Glomerular Serpina3 expression in 129S6/SvEv and C57BL/6 mice subjected to DOCA-salt 
uninephrectomy, examined using immunofluorescence microscopy. A) Representative immunofluorescence 
staining of Serpina3 at 1, 7 and 42 days (red) shows increased glomerular expression in C57BL/6 mice, most 
strongly at 42 days. The immunostaining in the glomerulus appears to be localized to the peripheral capillary 
walls. Immunoreactivity for Serpina3 is also apparent in surrounding tubular epithelium at all time points in 
both strains, and appears to increase mildly over time. B) Immunocostaining of Serpina3 with podocyte-
specific marker synaptopodin (SYNP; green) displayed increased expression in podocytes. Areas of 
colocalization, which appear yellow in the two figures on the right, appear to outline the peripheral capillary 
wall and potentially correspond to podocyte foot processes.  
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Upregulation of Upstream Regulator STAT3 Expression in C57BL/6 Mice 
Given the significant glomerular activation of the Acute Phase Response signaling 
pathway gene set in response to hypertension, we were interested in identifying possible 
upstream transcriptional regulators of this gene set which may be activated in C57BL/6 
mice. Ingenuity Pathway Analysis Upstream Regulator Analysis Tool was used to identify 
possible upstream regulators of this pathway. The analysis predicted activation of the 
transcription factor Signal Transducer and Activator of Transcription 3 (Stat3). Gene 
expression analysis revealed Stat3 to be upregulated in C57BL/6 mice on day 7. Therefore 
we peformed immunohistochemistry to characterize Stat3 protein expression in glomeruli 
of mice subjected to DOCA-salt uninephrectomy. Stat3 was found to be expressed in the 
podocytes of C57BL/6 mice (Figure 18), with strongest immunoreactivity seen at 42 days. 
These findings provide strong evidence of activation of the Acute Phase Response 
Signaling pathway in podocytes of C57BL/6 mice which might confer resistance to 
glomerular damage and accelerate healing in response to mechanical stress-induced injury 
associated with hypertension. 
We then examined whether STAT3 was phosphorylated using antibodies 
recognizing Tyr705. Our results showed that phosporylated-STAT3 staining was 
predominantly seen in the nuclei of glomerular endothelial cells and relatively lower 
expression was detected in the nuclei of podocytes (Figure 19B) in the C57BL/6 mice. 
These finding were largely found among the juxtamedullary glomeruli. Moreover, the 
expression of p-STAT3 was not limited to the glomeruli, but also observed in the tubules 
of C57BL/6 mice Figure 19C). 
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Figure 18. Upregulation of Stat3 protein in podocytes of C57BL/6 mice in response to systemic 
hypertension. A) Representative immunofluorescence staining of Stat3 protein (red) at baseline (day 0) and 
at 1, 7 and 42 days shows increased glomerular expression in C57BL/6 mice, most strongly at 42 days. The 
immunostaining in the glomerulus appears to be localized to the peripheral capillary walls. Immunoreactivity 
for Stat3 protein is absent in surrounding tubules. B) Immunocostaining of Stat3 protein with podocyte-
specific marker synaptopodin (SYNP; green) showing increased Stat3 expression in podocytes. Areas of 
colocalization, which appear yellow in the two figures on the right, appear strongest in podocyte cell bodies. 
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Figure 19. Glomerular STAT3 activation (p-STAT3). Immunofluorescence staining of p-STAT3 in mice 
kidneys in response to systemic hypertension induced by DOCA-salt uninephrectomy in wild-type C57BL/6 
and 129S male mice. (A) The number of p-STAT3 positive glomerular cells increased by day 7 in the 
C57BL/6 mice. (B) phosporylated-STAT3 staining was predominantly seen in the nuclei of glomerular 
endothelial cells and podocytes. C) The expression of p-STAT3 was not limited to the glomeruli, but also 
observed in the tubules of C57BL/6 mice.  
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Upregulation of Ptprv in Kidneys of 129S6/SvEv Mice 
In contrast to the C57BL/6 mice, the most strongly induced gene in the glomeruli 
of 129S6/SvEv mice in response to hypertension was Protein Tyrosine Phosphatase 
Receptor Type v (Ptprv), which was upregulated at all time points in the 129S6/SvEv mice 
(Figure 14). Intriguingly, the baseline log2 expression level of Ptprv was also higher in 
129S6/SvEv glomeruli prior to intervention (Figure 13B). Immunohistochemistry for Ptprv 
protein revealed intense immunoreactivity along the glomerular arterioles, particularly the 
afferent arteriole (Figure 21). Prior to intervention, the receptor expression was limited to 
the vascular pole immediately adjacent to the glomeruli, and after the intervention, 
immunoreactivity appeared to extend along the entire length of the arterioles (Figure 21). 
Although gene expression analysis was performed using isolated glomeruli, it is likely that 
distal portions of glomerular arterioles were isolated along with the glomeruli and therefore 
were present in the samples that were analyzed (Figure 20). Thus it is plausible that a 
gene/protein exclusively expressed in arterioles may be detected by our analysis. Indeed, 
distal arteriolar segments are often seen attached to isolated glomeruli when examined 
microscopically. 
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Figure 20. Isolated segments of glomerular arterioles. Distal portions of glomerular arterioles (arrows) 
are isolated along with the glomeruli when using the iron oxide method of glomerular isolation. 
 
Since human kidneys are thought to be generally susceptible to hypertension-
associated glomerular damage, similarly to 129S6/SvEv kidneys, we were interested to 
know whether the PTPRV receptor, analogous to murine Ptprv, could be detected in human 
kidneys. PTPRV expression has not been described in the kidney to date. To explore this 
possibility, we immunostained normal human kidney for PTPRV protein. In the human 
kidney, immunoreactivity of PTPRV protein was detected at the vascular pole in some of 
the glomeruli (Figure 22). Thus the PTPRV receptor exhibited a similar expression pattern 
in human kidneys as that of the Ptprv receptor seen in murine 129S6/SvEv kidneys at 
baseline. 
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Figure 21. Ptprv expression in C57BL/6 and 129S6/SvEv mice subjected to DOCA-salt 
uninephrectomy, examined using immunofluorescence microscopy. (A and B) Representative 
immunofluorescence staining of Ptprv (red) at baseline (day 0) and 1, 7 and 42 days shows expression in 
glomerular arterioles in both C57BL/6 and 129S6/SvEv mice, most strongly at 42 days. The immunostaining 
in 129S6/SvEv kidneys at 7 and 42 days appears to extend proximally in the arterioles relative to C57BL/6 
mice and 129S6/SvEv mice at baseline and 1 day post-operatively, consistent with upregulation of expression 
in the arterioles. (C) Bar chart illustrating fold change of Ptprv mRNA expression at 1, 7, and 42 days post-
operatively, for both C57BL/6 and 129S6/SvEv strains, as determined from microarray studies. Expression 
of Ptprv mRNA is substantially higher in 129S6/SvEv mice at all time points relative to C57BL/6 mice. D) 
Quantification of immunoreactivity of Ptprv in glomerular arterioles of C57BL/6 and 129S6/SvEv mice at 
baseline (day 0) and 1, 7 and 42 days showing percentage of Ptprv positive glomerular arterioles. Proportion 
of Ptprv-positive arterioles is significantly greater in 129S6/SvEv mice relative to C57BL/6 mice at 7 and 42 
days. Data are presented as mean value (±) SE. * P < 0.005.  
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Figure 22. PTPRV protein expression in human kidney. Representative immunofluorescence staining for 
PTPRV (red) shows positive immunoreactivity for PTPRV protein that is limited to the glomerular ateriolar 
walls at the vascular pole immediately adjacent to the glomerular tuft. 
 
Kidney Proliferation Marker 
Ki-67 is a nuclear antigenic marker of cell proliferation, which is only expressed in 
actively cycling cells88. Its gene was also found among the top differentially expressed 
genes in the microarray data set. Therefore, immunohistochemical localization of Ki-67 
was conducted and a minimum of 60 glomeruli/mouse were examined, in addition to 
examination of the tubulointerstitium. Interestingly, the number of glomerular and 
tubulointerstitial cells immunoreactive to Ki-67 at 7 and 42 days was significantly elevated 
in both strains compared to their baselines (Figure 23). However, the C57BL/6 mice show 
a more dramatic upregulation of proliferating cells compared to the 129S mice in both the 
glomerular and tubulointerstitial compartments (Figure 23A,C). To identify the 
proliferating glomerular cells, immunohistochemical co-localization of WT-1, a specific 
nuclear podocyte marker, was performed along with Ki-67 immunostaining. Ki-67 did not 
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colocalize with WT-1, indicating that cells other than the podocyte were proliferating, such 
as the mesangial and the parietal glomerular epithelial cells (Figure 23B).  
 
 
 
 
 
 
  
70 
 
Figure 23. Cellular proliferation in the glomerulus and tubulointerstitium of C57BL/6 and 129S6/SvEv 
mice in response to systemic hypertension. Immunofluorescence staining for Ki-67 (red), a nuclear marker 
of cell proliferation, in murine kidneys in response to systemic hypertension induced by DOCA/salt 
uninephrectomy in wild-type C57BL/6 and 129S6/SvEv male mice. (A) The proportion of Ki-67 positive 
cells in the glomerulus and surrounding parietal epithelium appears to increase after treatment and appears 
to peak at day 7 post operatively in both strains. (B) The glomerular Ki-67 positive cells (red) in C57BL/6 
glomeruli at day 7 were observed in the parietal epithelium lining Bowman’s capsule and within the 
glomerular tuft, and did not appear to co-localize with podocyte-specific nuclear marker, Wilms’ Tumor-1 
(WT-1; green). (C) Low magnification images of immunofluorescence nuclear staining for Ki-67 (red) in 
murine kidneys in DOCA/salt uninephrectomy treated C57BL/6 and 129S6/SvEv mice, to show tubular 
epithelial staining. Peak proliferation of cells within the tubulointerstitium compartment was observed at day 
7, particularly in C57BL/6 compared to the 129S mice (* P < 0.005). (D) Ki67 fold changes. (D and E) 
Quantification of Ki-67 immunostaining in murine kidneys in DOCA/salt uninephrectomy treated C57BL/6 
and 129S6/SvEv mice; D) Glomerular quantification expressed as number of positive cells per glomerular 
cross section (GCS); E) Tubulointerstitial quantification. (** P < 0.005); (* P < 0.05). n = 3 per treatment 
group. Error bars, S.E.M. 
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Upstream Effector of Acute Phase Response Signaling Pathway 
Our initial findings demonstrate that the Acute Phase Response signaling pathway 
is activated in the podocytes of C57BL/6 mice in response to hemodynamic stress. Based 
on Ingenuity Pathway Analysis, this pathway is activated in response to tissue stress/injury 
through interleukin-6 (IL-6) receptor signaling. Here we wanted to determine whether IL-
6 affected the expression of STAT3 and its activation, and expression of its downstream 
effector molecules in podocytes. To do this, we isolated primary mouse podocytes in 
primary culture (Figure 24) and challenged these primary cultures with IL-6 (100 ng/ml) 
for 30, 90, and 180 minutes after 24-hour serum starvation.  Similar to our mouse model 
findings, immunoblotting analysis showed increase in STAT3 expression and 
phosphorylation (Y705) in response to IL-6 stimulation. Intriguingly, Serpina3, a 
downstream effector of STAT3, expression levels also increased in podocytes (Figure 25). 
Collectively, these finding suggest that IL-6/STAT3 signaling may mediate the expression 
of Serpina3 and potentially other downstream effectors in podocytes. 
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Figure 24. Mouse primary podocyte culture. A) Mouse glomeruli were isolated using the iron oxide 
method as described in Figure 3. The isolated glomeruli were suspended in RPMI 1640 medium 
supplemented with 10% FBS and plated on collagen-coated Petri dishes. By day 3, primary cell outgrowths 
were trypsinized and glomerular cores were removed using a magnetic concentrator. Phase contrast 
brightfield photomicrographs show plated glomeruli at day 0, and at day 3 along with cellular outgrowth, 
immediately before trypsinization. B) Podocyte purity in primary cultures was confirmed using a podocyte 
specific nuclear marker, WT-1, and alpha smooth muscle actin as a negative control (α-SMA). Vascular 
smooth cells (VSMC) were used as negative controls for WT-1 and a positive control for α-SMA. 
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Figure 25. Cell culture assay. A) Interleukin-6 stimulates Serpina protein expression, and STAT3 protein 
expression and tyrosine phosphorylation in podocytes. Primary murine podocytes were treated with 100 
ng/ml IL-6 at different intervals as indicated. Cell lysates were subjected to Western blot analysis with anti-
Serpina3, anti-phospho-Tyr705 STAT3 (pTyr-STAT3) and anti-STAT3. IL-6 increases Serpina3 protein, 
STAT3 protein, and total STAT3 tyrosine phosphorylation in a time-dependent manner and caused STAT3 
activation as early as 30 minutes. B) Expression of stress proteins in primary murine podocyte culture after 
DOCA challenge. DOCA had no effect on expression of stress proteins HSP27 and HSP90A. 
 
DOCA has effects on kidney physiology and we use DOCA in this study to help 
modulate glomerular hemodynamics indirectly through its effect on systemic blood 
pressure. To rule out a direct effect of DOCA on glomerular cells, the expression of stress 
proteins HSP27 (Heat shock protein 27) and HSP90A (Heat shock protein 90A) in primary 
podocytes was examined after challenge with DOCA for 2 days. The experiment yielded 
no appreciable change in HSP27 and HSP90A expression or activation (Figure 23). 
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Discussion  
The past two decades of research has yield a wealth of new information and 
extraordinary growth in understanding kidney disease pathophysiology. However, despite 
these advances and advances in research tools, the incidence and prevalence of CKD and 
ESRD remains high with no evidence that they will drop significantly any time soon2,14. 
Moreover, the social and financial burden of CKD is increasing resulting in poor quality 
of life, premature morbidity, and high health care costs. This phenomenal increase in CKD 
parallels the increase in essential hypertension prevalence globally89. As we stated in the 
introduction, these findings are more profound among African Americans. This differential 
susceptibility has been attributed to genetic variations on chromosome 22 in humans. In 
mice, intriguingly, the genetic background determines their susceptibility to several types 
of diseases including progressive kidney disease. For example, in murine models of 
glomerular hypertension, C57BL/6 are found to be relatively resistant to severe glomerular 
injury compared to 129S6/SvEv mice. Thus, it is clear that genetic background contributes 
to kidney disease development in humans and experimental mouse models.   
Traditionally, hypertension-associated glomerular lesions are characterized by 
mesangial cell proliferation and accumulation of extracellular matrix. More recently, there 
has been more focus on the role of the podocyte in glomerular disease developing in 
response to systemic hypertension, particularly when podocyte injury is considered a 
hallmark of proteinuric glomerular diseases. However, the cause of hypertension-induced 
podocyte injury in models of systemic hypertension remains poorly understood. 
Mechanical forces have been postulated to induce strain on podocyte foot processes 
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because of increased hydrostatic pressure or hyperfiltration. Non-hemodynamic causes 
including oxidative stress have also been suggested as a direct effect of aldosterone and 
vasoactive compounds82. 
The glomerulus is directly affected by changes in the systolic blood pressure and is 
the primary site of kidney lesions in conditions of systemic hypertension. Molecular 
mechanisms underlying the induction and progression of hypertension induced glomerular 
disease are not well understood. In this study, we performed glomerular profiling analysis 
to dissect novel molecular networks responsible for hypertension associated glomerular 
damage, using an experimental model of hypertension-induced CKD in mice on different 
genetic backgrounds. We found that each of the two murine strains investigated exhibited 
a unique glomerular transcriptome profile that paralleled their strain-specific responses to 
hypertension over time.  
In the 129S6/SvEv mice, the most differentially expressed gene in the glomeruli in 
response to systemic hypertension was the gene encoding Protein Tyrosine Phosphatase 
Receptor Type v, Ptprv. Our initial analysis revealed higher baseline expression levels of 
Ptprv in 129S6/SvEv mice compared to the C57BL/6 mice. Previous studies have 
independently identified blood pressure QTLs (quantitative trait loci) located on 
chromosome 1 between position 43 and 73 cM in different mouse models, including salt-
induced hypertension mouse models80,90-92. Interestingly, the Ptprv gene is mapped to 
chromosome 1 within the exact same locus, precisely at 58.24 cM32. The most recent of 
these prior studies involved study of renal and vascular responses to subtotal nephrectomy 
in C57BL/6 and 129S mice. None of these studies has physically refined this locus to the 
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underlying genes. Based on the enhanced expression and site of Ptprv receptor, it could be 
potentially playing a role in regulating the glomerular blood flow and glomerular filtration 
rate. To date, no one has localized the expression site of Ptprv in the kidney, reported the 
role of Ptprv in the pathophysiology of hypertension and kidney disease, or identified a 
receptor ligand to Ptprv. This is understandable, since the expression of Ptprv appears to 
be induced and focal, which would have made it challenging to characterize Ptprv in the 
whole kidney lysate by other investigators whom first characterized the receptor93,94.  
Among the most strongly induced genes in the C57BL/6 mice identified in our 
experiment are the gene encoding Serine Protease Inhibitor A3, Serpina3, and the genes 
encoding the Fibrinogen chains alpha, beta, and gamma (Fga, Fgb, and Fgg, respectively). 
Our results show that by day 7, enhanced glomerular expression of Fgb and Fgg was seen, 
and immunolocalization revealed these proteins to be localized to the podocytes, taking a 
granular cytoplasmic pattern. Fibrinogen is primarily synthesized in the liver, and functions 
as a circulating plasma protein, playing a key role in blood coagulation. However, 
extrahepatic synthesis of fibrinogen chains has been reported in the epithelium of the 
proximal tubules, intestine95, cervix96, and lung97,98. These findings suggest different 
alternative functions of fibrinogen chains in other structures. Beside its role in clot 
formation, it also plays a pivotal role in regulating inflammatory responses, tissue repair, 
cell adhesion, and cell migration through its interaction with immune cell receptors 
including integrins99,100. In a recent study, Krishnamoorthy et al showed significant 
upregulation of endogenous Fgα, Fgβ, and Fgγ in murine kidneys in response to bilateral 
renal ischemic reperfusion injury101. They found the expression of the fibrinogen chains to 
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be localized to kidney tubules, and they also detected fibrinogen in the urine. In the same 
study, they demonstrated that fibrinogen-derived β peptide elicits nearly 50% protection 
from bilateral ischemia when administered intravenously at time of injury by increasing 
renal tissue repair and decreasing apoptosis101. Thus secreted or intracellular fibrinogen 
may have a role in protecting glomerular cells from injury under conditions of stress. 
Serpina3 was also detected in podocytes in C57BL/6 mice in response to systemic 
hypertension. The serine protease inhibitors, also known as serpins, are the largest protease 
inhibitor super family and are divided into 16 clades102. Serpina3 is the mouse orthologue 
of the human anti-chymotrypsin and has been identified as an inhibitor of several proteases 
derived from activated inflammatory cells, including human leukocyte elastase, cathepsin 
G, granzyme B and chymase102-104. Several proteases can accumulate in extracellular 
matrix (ECM) during chronic inflammation and cleave ECM proteins, including 
fibronectin, that are essential for proper tissue healing102. Several recent studies have 
demonstrated the efficiency of serpina3 in accelerating tissue repair in murine models of 
chronic inflammatory diseases such as wound healing in type II diabetes105 and aortic 
aneurysms104. To date, however, the role of serpina3 in chronic kidney disease remains 
unknown. Given the known function of related serine protease inhibitors, it is plausible 
that upregulation of Serpina3 in C57BL/6 mice may protect the ECM of the glomerulus 
from damage, or promote its repair, in states of glomerular hypertension-associated stress. 
Based on hierarchical gene cluster analysis, the fibrinogen chains and Serpina3 
belong to the same cluster. Upstream regulator and pathway analysis revealed activation 
of the Acute Phase Response Signaling pathway and its proximal transcription regulator 
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Stat3 which was confirmed to be expressed in podocytes in the C57BL/6 mice. IPA 
upstream regulator analysis tool was used to determine the possible upstream 
transcriptional regulators of this gene set in the C57BL/6 mice, and the analysis predicted 
induced activation of the transcription factor signal transducer and activator of transcription 
3 (Stat3). Intriguingly, Stat3 was found to be upregulated in C57BL/6 mice at day 7 post 
exposure to hypertension model. The expression of Stat3 was confirmed to be localized to 
the podocytes of C57BL/6 mice (Figure 18), as is the case with Serpina3 and the Fibrinogen 
chains. Collectively, these finding provide strong evidence of activation of the Acute Phase 
Response Signaling pathway in podocytes of C57BL/6 mice which might confer resistance 
to glomerular damage and accelerates healing in response to mechanic induced injury in 
response to hypertension. Further studies using the gene expression data described here 
may reveal additional pathways that are critical to development or progression of damage 
associated with glomerular hypertension. 
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Conclusion 
Various animal models of experimental hypertension have been developed to study 
the pathogenesis of glomerular disease in response to systemic hypertension, the second 
leading cause of CKD after diabetes. A clinically relevant model is the deoxycorticosterone 
acetate (DOCA) salt uninephrectomy model. Hypertension in this model results from high-
salt intake, hypervolemia, and hyperaldosteronism, important contributors to hypertension 
in humans. Utilizing this model in mice, the results presented in this study demonstrate a 
number of features consistent with CKD in humans, including hypertension, albuminuria, 
and glomerulosclerosis. However, these results vary based on the mouse strain background. 
Our results show that C57BL/6 and 129S6 inbred mice exhibited distinct differences in the 
development of glomerular injury. 129S6 mice developed significant glomerular injury 
compared to C57BL/6 despite the similar blood pressure changes in response to DOCA/salt 
uninephrectomy.  
In this study, we compared glomerular gene expression differences in the two 
strains of mice at baseline and after induction of systemic hypertension. Our results 
demonstrate, for the first time, that C57BL/6 and 129S6 have distinctly different 
glomerular transcriptome genetic signatures, which we believe are responsible, in part, for 
the glomerular variation in response to hemodynamic stress. The variability in gene 
expression pattern across the strains over time was strikingly different, affirming the large 
genetic diversity between the strains and their responses to hemodynamic stress. The most 
differentially expressed gene in the 129S6 mice was the Protein Tyrosine Phosphatase 
Receptor Type v, Ptprv. Intriguingly, our initial analysis revealed higher baseline 
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glomerular expression levels of Ptprv in 129S6 mice compared to the C57BL/6 mice, and 
its expression was immunolocalized to the glomerular arterioles. On the other hand, among 
the most strongly induced genes in the C57BL/6 mice identified in this study are the gene 
encoding Serine Protease Inhibitor A3, Serpina3, and the genes encoding the Fibrinogen 
chains alpha, beta, and gamma (Fga, Fgb, and Fgg, respectively). Immunolocalization 
revealed these proteins to be localized to the podocytes. Furthermore, we measured the 
stiffness of glomeruli, expressed as elastic modulus, and characterized its change overtime. 
Our results demonstrated that 129S mice show greater variation over time compared to 
C57BL/6. 
One limitation of this study was the lack of intra-glomerular capillary pressure 
measurements in living intact glomeruli. How the elevation in systemic blood pressure 
translates into the glomerular capillary pressure is not well understood in mice. These 
measurements will be particularly beneficial, as this will allow us to identify differences in 
the mechanical behavior of glomerular cells in C57BL/6 and 129S6 mice. 
In summary, our study compared glomerular gene expression differences in 
response to systemic hypertension utilizing a mouse strain that is susceptible to severe 
glomerular injury (129S6), and a relatively resistant mouse strain (C57BL/6), to identify 
genes specifically associated with the development of hypertension-associated glomerular 
injury. The increased understanding of the molecular mechanisms underlying 
hypertension-associated podocyte injury and glomerular damage which will result from 
these studies, will ultimately lead to identification of novel pharmacologic targets or 
therapeutic strategies for patients with hypertension and renal disease.
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